Post Resch Tallon Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$921K Buy
32,293
+1,751
+6% +$46.6K 0.63% 35
2026
Q2
$735K Buy
30,542
+1
+0% +$26 0.51% 42
2026
Q1
$864K Buy
30,541
+15
+0% +$399 0.7% 36
2025
Q4
$760K Buy
30,526
+14,065
+85% +$355K 0.64% 37
2025
Q3
$419K Hold
16,461
– – 0.37% 52
2025
Q2
$399K Sell
16,461
-650
-4% -$15.2K 0.38% 50
2025
Q1
$421K Sell
17,111
-2,003
-10% -$52.4K 0.43% 47
2024
Q4
$509K Buy
+19,114
New +$518K 0.49% 43

Other funds holding PFE

Post Resch Tallon Group's PFE Position: Q3 2026 in Review

Post Resch Tallon Group increased its Pfizer (PFE) stake by 5.7% in Q3 2026, buying an estimated $46.6K and bringing the position to 32,293 shares worth $921K. The position accounts for 0.63% of the portfolio, ranked #35.

Post Resch Tallon Group first reported a position in PFE in Q4 2024 and has held it in 8 quarters since. 2,899 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Post Resch Tallon Group held 32,293 shares of Pfizer worth $921K as of Q3 2026.
  • Post Resch Tallon Group bought 1,751 Pfizer shares in Q3 2026, an estimated $46.6K.
  • Pfizer made up 0.63% of Post Resch Tallon Group's portfolio in Q3 2026, its #35 holding.
  • Post Resch Tallon Group first reported a position in Pfizer in Q4 2024 and has held it in 8 quarters since.
  • 2,899 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Post Resch Tallon Group's 13F filing for Q3 2026, filed 9 Oct 2026.